Mode
Text Size
Log in / Sign up
N/A N=30 Prevention

Buoy Electrolyte Study on Hydration Status of Active Men and Women

Dehydration · Electrolyte Imbalance · Electrolyte Depletion · Fluid and Electrolyte Imbalance

Enrolled (actual)
30
Serious AEs
0.0%
Results posted
May 2025
Primary outcome: Primary: Net Fluid Balance — 0.28; 0.05; 0.03 Liter

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Buoy Electrolyte (Dietary_supplement); Water only (Other); Nuun Electrolyte (Dietary_supplement)
Age
Adult · 18+ yrs
Sex
All
Sponsor
University of Pittsburgh
Primary completion
Apr 2024

Outcome Measures

OutcomeResultp-value
PRIMARY
Net Fluid Balance
0.28; 0.05; 0.03
PRIMARY
Electrolytes in Urine
39; 58; 48
PRIMARY
Urine Osmolarity (mOsm/kg)
1928; 1666; 1866
SECONDARY
Bio Impedance
0.75; 0.64; 0.44

Summary

Buoy is an all-natural, organic, FDA compliant dietary electrolyte supplement that can be dissolved in 8-12oz water (or other liquid) and provide electrolytes in servings of 1/3 teaspoon. This study will evaluate Buoy in hydrating active adults.

Eligibility Criteria

Inclusion Criteria

  • Male or female, >18 to 45 years of age
  • Freely given written consent
  • Non-tobacco users
  • Negative pregnancy test in women of childbearing potential
  • BMI 60 ml/min
  • No known underlying medical condition
  • Willing to refrain from EtOH for 24h prior to test day
  • Willing to refrain from strenuous exercise for 24 h prior to each test day
  • Acceptable to have one 8oz cup of coffee/liquid on the morning of the test, but must be consistent each visit
  • Without active infection of any kind
  • Engaged in exercise three or more hours per week

Exclusion Criteria

  • Abnormal creatinine (Cr > 1.2).
  • Proteinuria / hematuria / glucosuria based on urine dipstick.
  • Diagnosed medical condition that would impede results (CHF, HTN, CAD, CKD, history of electrolyte abnormality).
  • Pregnancy
  • Use of diuretics within past 2 weeks
  • Obesity (BMI > 35)
  • Active infection based on symptoms (bacterial or viral)
  • Hemodynamic abnormality at screening visit: Blood pressure less than 100/60 or greater than 140/90.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT05768789). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search